Related Experiment Video
Updated: Sep 13, 2025

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
Published on: June 4, 2020
[Use of thromboelastography prior to systemic thrombolysis in patients treated with DOACs - case series]
Lóránd Hegyi1, Péter Klivényi1,2, Alex Beke1
1Szegedi Tudományegyetem, Szent-Györgyi Albert Orvostudományi Kar, Szent-Györgyi Albert Klinikai Központ, Neurológiai Klinika, Szeged.
Insights
Direct oral anticoagulants (DOACs) complicate acute ischemic stroke treatment. Viscoelastic tests like RVV and ECA rapidly assess DOAC effect, aiding thrombolysis decisions in patients with unknown anticoagulant history.
Area of Science:
- Cardiology
- Neurology
- Hematology
Background:
- Direct oral anticoagulants (DOACs) are increasingly used, posing challenges for acute ischemic stroke management.
- Thrombolysis is contraindicated within 48 hours of DOAC intake, necessitating accurate compliance assessment.
- Accurate patient history of DOAC use is often unavailable, complicating treatment decisions.
Observation:
- Viscoelastic tests, specifically Russell's viper venom (RVV) and Ecarin assay (ECA), were performed using a thromboelastograph.
- These tests were applied to 25 acute ischemic stroke patients with uncertain DOAC history.
- The tests provided information on anticoagulant effect and patient compliance based on coagulation time.
Findings:
- DOAC therapy ineffectiveness was observed in 11 cases, with 9 confirmed by heteroanamnesis.
- Thrombolysis was enabled in 4 patients based on test results.
- One hemorrhagic complication occurred, linked to undiagnosed chronic lymphocytic leukemia.
Implications:
- DOAC-specific viscoelastic tests (RVV, ECA) offer rapid assessment of recent DOAC intake (within 48 hours).
- These tests facilitate identification of eligible patients for thrombolysis.
- The assays assist clinicians in determining compliance, assessing thrombolysis possibility, and expediting treatment decisions.
Abstract:
The number of patients treated with direct oral anticoagulants (DOACs) is significantly increasing. In acute ischemic stroke, systemic thrombolysis is currently contraindicated for patients who have received DOAC treatment within the last 48 hours. Therefore, it is crucial to assess the continuity of treatment and patient compliance. However, accurate history is often unavailable. The anticoagulant effect of DOACs can be detected using viscoelastic tests performed by the thromboelastograph (ClotPro®). In our study, we conducted Russell's viper venom (RVV) and Ecarin assay (ECA) tests using a thromboelastograph in 25 patients with acute ischemic stroke who were potentially taking DOACs but were unable to provide an accurate history. Based on the coagulation time, we obtained information regarding the effect of the anticoagulant treatment, and thus compliance, which aided in assessing the eligibility for thrombolysis. In 11 cases, we observed the ineffectiveness of the DOAC therapy, 9 of which were later confirmed by heteroanamnesis. These tests enabled thrombolysis in 4 patients. Hemorrhagic complication was observed in one case, which was caused by an underlying, previously undiagnosed chronic lymphocytic leukemia. In the cases we observed, DOAC-specific viscoelastic tests (RVV, ECA) provided rapid information regarding DOAC administration within the last 48 hours, allowing the identification of the patients who were eligable for thrombolysis. Overall, these tests assist clinicians in determining compliance, assessing the possibility of thrombolysis, and reducing the time required to make treatment decisions.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Acute Coronary Syndrome III: Diagnostic Studies

